Features Partner Sites Information LinkXpress
Sign In
Advertise with Us
RANDOX LABORATORIES

Gene Vaccine Protects Mice from Influenza Virus Strains

By BiotechDaily International staff writers
Posted on 13 Nov 2017
Print article
Image: A scanning electron micrograph (SEM) of the influenza virus (Photo courtesy of the CDC).
Image: A scanning electron micrograph (SEM) of the influenza virus (Photo courtesy of the CDC).
A team of molecular virologists protected mice from deadly infection caused by a range of influenza viruses by using a deactivated adenovirus vector to vaccinate them with a cocktail of centralized viral genes.

In a study conducted by investigators at the University of Nebraska, Lincoln (USA), mice were immunized with replication-defective adenovirus expressing the H1-con, H2-con, H3-con, and H5-con HA (hemagglutinin) consensus influenza virus genes in combination (multivalent) and compared to mice immunized with the traditional 2010–2011 FluZone and FluMist seasonal vaccines. The mice were then challenged with 10–100 MLD50 (the median lethal dose required to kill half the population) of H1N1, H3N1, H3N2 and H5N1 influenza viruses.

The investigators reported in the November 2, 2017, online edition of the journal Scientific Reports that the traditional vaccines induced robust levels of HA inhibition (HI) titers, but failed to protect against five different heterologous lethal influenza challenges. Conversely, the multivalent consensus vaccine induced protective HI titers against eight of 10 influenza viruses that represented a wide degree of divergence within the HA subtypes and protected 100% of mice from eight of nine lethal heterologous influenza virus challenges.

The vaccine protection was dose dependent, in general, and a low dose still provided 100% survival against seven of nine lethal heterologous influenza challenges. These data indicated that very low doses of adenovirus-vectored consensus vaccines induced superior levels of immunity against a wide divergence of influenza subtypes as compared to traditional vaccines.

"Our idea is that these centralized antigens can set up a foundation of immunity against influenza," said senior author Dr. Eric Weaver, assistant professor of biological sciences at the University of Nebraska, Lincoln. "Because they are centralized and represent all the strains equally, they could provide a basis for immunity against all evolved strains. An ideal influenza vaccine would be inexpensive, provide long-lasting immunity, require few immunizations, and would work against all variants of the virus. The ultimate goal is to be able to vaccinate once and provide lifelong protection."

Related Links:
University of Nebraska, Lincoln


Print article

Channels

Business

view channel

Collaborative Agreement to Aid in Setting Guidelines for Evaluating Potential Ebola Therapy

Cooperation between an Israeli biopharmaceutical company and medical branches of the US government is designed to set ground rules for continued evaluation of an experimental therapy for Ebola virus disease. RedHill Biopharma Ltd. (Tel Aviv, Israel), a biopharmaceutical company primarily focused on development and c... Read more
Copyright © 2000-2017 Globetech Media. All rights reserved.